Biotechnology company Amgen Inc (NASDAQ: AMGN) announced on Monday that it presented new data for its first-in-class bispecific T-cell engager, IMDELLTRA (Tarlatamab-dlle), targeting DLL3 in extensive-stage small cell lung cancer (ES-SCLC) during the World Conference on Lung Cancer (WCLC) 2024. Results from the Phase 1b DeLLphi-303 study demonstrated that IMDELLTRA, in combination with PD-L1 inhibitors, serves as an effective first-line maintenance therapy.
Findings highlighted manageable safety and positive survival outcomes from the combination therapy. In the IMDELLTRA and Durvalumab arm, the disease control rate was 62.5%, with a 9-month overall survival of 91.8% and a median progression-free survival of 5.3 months. In the IMDELLTRA and Atezolizumab cohort, a similar disease control rate of 62.5% was noted, with a median duration of disease control at 7.2 months and a 9-month overall survival of 86.7%.
Long-term follow-up data from the DeLLphi-301 Phase 2 study reaffirmed the drug's sustained efficacy and safety in previously treated ES-SCLC patients. The objective response rate was 40% among 100 patients, with a median overall survival of 15.2 months.
Safety profiles indicated treatment-related adverse events, with Durvalumab resulting in 15% dose interruptions and Atezolizumab at 17%. Cytokine Release Syndrome primarily manifested as grade 1-2, while Immune effector cell-associated neurotoxicity syndrome occurred infrequently.
IMDELLTRA, which targets DLL3 on cancer cells and CD3 on T cells, received accelerated FDA approval on 16 May 2024 for patients experiencing disease progression after platinum-based chemotherapy. Ongoing studies will further clarify its efficacy and safety profile in treating this challenging malignancy.
Genprex research collaborators to present positive data on Reqorsa Gene Therapy at SITC 2024
hVIVO reports positive results from RSV antiviral human challenge trial
BerGenBio reveals preliminary safety data from Phase 1b BGBC016 study in first-line NSCLC patients
Liquidia and Pharmosa expand collaboration for inhaled treprostinil
Alvotech launches confirmatory study for Entyvio biosimilar
Merck's KEYTRUDA receives new approvals in Japan for lung and urothelial cancers
Innate Pharma receives FDA clearance of IND for IPH4502, a Nectin-4 targeting ADC for solid tumours
Intas Pharmaceuticals reports positive opinion for HETRONIFLY in Europe
Insilico Medicine reveals positive preliminary results from ISM001-055Phase IIa clinical trial
NeoGenomics to present breakthrough data at ESMO 2024 on ctDNA and NGS for cancer diagnostics
OSE Immunotherapeutics initiates Phase 3 trial for cancer vaccine Tedopi
AbbVie advances solid tumour pipeline with new data at ESMO 2024
Amgen showcases promising data for IMDELLTRA in small cell lung cancer at WCLC 2024